Cidara Therapeutics, Inc.

CDTXNASDAQHealthcare

$221.38

+$0.00(+0.00%)

Market Cap$5.6B

P/E Ratio—

52W High$221.42

52W Low$15.22

Avg Volume1.4M

Open$221.38

Beta1.53

Free Cash Flow Financials Revenue

Cidara Therapeutics, Inc. (CDTX) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

CDTX · free cash flow · updated Jun 8, 2026

Core FCF metrics

CDTX · FCF · TTM · margin & CAGR

Free cash flow was −$176.7M for FY2024 (fiscal year ending 2024-12-31), down 670.2% year-over-year

FY2024 Free Cash Flow−$176.7M▼ -670.2% YoY

Trailing 12M (TTM)−$132.9Mtrailing 4 quarters sum

FCF Margin< −999%−$176.7M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

CDTX · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2024Latest−$176.5M(0M)−$176.7M▼ 670.2%—

FY2023−$22.4M(1M)−$22.9M▲ +19.8%-98.5%

FY2022−$28.5M(0M)−$28.6M▼ 13.1%-44.4%

FY2021−$25.2M(0M)−$25.3M▲ +53.7%-51.0%

FY2020−$54.4M(0M)−$54.6M▼ 91.1%-452.4%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

CDTX · P/FCF · FCF yield · FCF per share

Cidara Therapeutics, Inc. (CDTX) reported negative free cash flow of −$0.18B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2024 · 2024-12-31

Cash flow statement summary

CDTX · cash flow statement · operating / investing / financing

For FY2024, Cidara Therapeutics, Inc. generated −$176.5M in operating cash flow and spent 0M in capital expenditures, yielding −$176.7M in free cash flow.

Operating Activities

−$176.5M

Cash from core business operations

2024-12-31

Investing Activities

−$0.1M

CapEx, acquisitions & investments

2024-12-31

Financing Activities

+$337.1M

Buybacks, dividends & debt

2024-12-31

FCF FormulaOperating CF (−$176.5M) − |CapEx| (0M) = FCF (−$176.7M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

CDTX vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Cidara Therapeutics, Inc.YOU

CDTX

−$176.7M-670.2%-13855.8%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Cidara Therapeutics, Inc. (CDTX) reported free cash flow of −$176.7M for FY2024 (fiscal year ending 2024-12-31), down 670.2% year-over-year.

Cidara Therapeutics, Inc. has reported negative free cash flow in recent periods, indicating capital expenditures have exceeded operating cash flow. Data available for 13 fiscal years.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

CDTX free cash flow · 8 questions

Cidara Therapeutics, Inc. free cash flow was −$176.7M for FY2024, down 670.2% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$132.9M.

CDTX free cash flowCDTX FCFCDTX FCF 2024CDTX free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Cidara Therapeutics, Inc. · Cidara Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026